The Phase I trial of MCARH109 CAR T-cell therapy, targeting GPRC5D for relapsed or refractory multiple myeloma, is sponsored by Memorial Sloan Kettering Cancer Center. Given the high unmet need in multiple myeloma, particularly among patients who have undergone multiple lines of therapy, this asset could capture significant market share if proven safe and effective. The competitive landscape includes existing CAR T-cell therapies targeting BCMA and other antigens, but GPRC5D represents a novel target that may provide therapeutic advantages. The trial's focus on safety and dose escalation will be critical for future development and potential commercialization. Investors should monitor the trial's progress and outcomes closely, as successful results could lead to partnerships or acquisition interest from larger biopharma companies.